Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline
MWN-AI** Summary
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leader in regenerative medicine, has achieved a significant regulatory milestone by securing its second International Nonproprietary Name (INN) from the World Health Organization (WHO). The proposed INN “etaroleucel” has been assigned to CELZ-101, the company’s innovative autologous regulatory T-cell (Treg) immunotherapy designed to promote immune tolerance in complex autoimmune conditions, particularly Type 1 diabetes in pancreatic islet transplantation. This milestone follows the WHO's previously established INN “olastrocel” for CELZ-201, an allogeneic cell therapy aimed at treating chronic lower back pain and degenerative disc disease.
Timothy Warbington, President and CEO of Creative Medical, emphasized the importance of these milestones as validation of the company's scientific advancements and regulatory capabilities. He noted that few companies in the regenerative medicine sector successfully navigate multiple platforms through the WHO INN process, and this dual recognition underscores the distinctiveness of Creative Medical's technologies and the evolving maturity of its clinical pipeline.
The recognition of both etaroleucel and olastrocel is crucial for the global clinical development and commercialization of these therapies. It positions Creative Medical favorably within the competitive landscape of regenerative medicine, enabling the company to pursue scalable solutions in high-unmet-need areas such as orthopedics, immunotherapy, and endocrinology. The firm's strategic focus on transforming innovative cell technologies is further bolstered by this regulatory standing, supporting its goal of delivering meaningful patient outcomes in the future.
Overall, Creative Medical Technology Holdings is forging ahead with its mission to provide impactful, disease-modifying therapies while navigating the complexities of global regulatory frameworks effectively.
MWN-AI** Analysis
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently bolstered its market position through significant regulatory milestones with the World Health Organization (WHO), achieving proposed International Nonproprietary Names (INN) for its cell therapy products CELZ-101 (etaroleucel) and CELZ-201 (olastrocel). This regulatory recognition indicates not only the quality of its science but also the company's ability to navigate complex global frameworks, critical for attracting investment and market credibility.
The proposed INN for etaroleucel reflects potential in addressing chronic autoimmune conditions, such as Type 1 diabetes, while CELZ-201 targets chronic lower back pain through allogeneic cell therapies. By diversifying its pipeline across significant unmet medical needs—including immunotherapy, orthopedics, and endocrinology—Creative Medical is positioning itself in lucrative markets. Analysts should consider these developments as a positive signal, reinforcing the company’s strategic ability to innovate and execute.
From an investment perspective, Creative Medical's recent advancements are likely to enhance its valuation, particularly as it aims for commercial pathways that hinge on successful clinical trials. Investors should monitor upcoming clinical trial data and regulatory developments, as these will be pivotal in determining market acceptance and competitive stance against established biotech firms.
However, investors should remain cognizant of the inherent risks associated with biotech investments, such as the unpredictability of clinical trial outcomes and regulatory approvals. The company’s forward-looking statements highlight these uncertainties, underscoring the necessity for a thorough risk assessment.
Overall, Creative Medical Holdings appears well-positioned for long-term growth within the regenerative medicine space, making it a compelling option for investors with an appetite for emerging biotech opportunities. The successful navigation of the regulatory landscape could foster significant returns as the company advances its innovative therapies toward commercialization.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.
The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List 134, following expert review during the 80th WHO INN Consultation (March 18–21, 2025). As part of the standard WHO process, the name is now entering the formal objection period prior to final confirmation.
CELZ-101 (etaroleucel) is designed to induce immune tolerance in complex autoimmune settings, including Type 1 diabetes in the context of pancreatic islet transplantation. The CELZ-101 platform has also been validated in cardiovascular and hepatic clinical applications.
This achievement follows WHO approval of “olastrocel” as the INN for the active cellular substance in CELZ-201, the Company’s lead allogeneic cell therapy also known as AlloStem®. This name was reviewed during the 79th WHO INN Consultation (October 22–25, 2024) and published in Proposed INN List 133, underscoring Creative Medical’s ability to advance multiple, distinct cell therapy programs through internationally recognized regulatory frameworks.
CELZ-201 (olastrocel) is being developed for chronic lower back pain and degenerative disc disease.
CEO Commentary
“Achieving proposed INN status for a second independent clinical program is a powerful validation of both our science and our regulatory execution,” said Timothy Warbington, President and CEO of Creative Medical. “Very few emerging regenerative medicine companies successfully advance multiple platforms through the WHO INN process. The recognition of both olastrocel and etaroleucel highlights the differentiation of our technologies and reflects the growing maturity of our pipeline.”
Warbington continued: “These milestones are not symbolic — they are foundational. INN recognition is essential for global clinical development, regulatory alignment, and eventual commercialization. We believe Creative Medical is building a scalable, internationally credible platform positioned for long-term value creation.”
Momentum Across the Pipeline
With both programs advancing through internationally recognized regulatory pathways, Creative Medical continues to execute on its strategy to translate innovative cell technologies.
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a clinical-stage biotechnology company pioneering regenerative medicine therapies derived from adult and perinatal stem cell technologies. The Company’s pipeline targets large, underserved markets across orthopedics, immunotherapy, endocrinology, urology, and gynecology, with a mission to deliver scalable, disease-modifying solutions for patients with high unmet medical needs.
For more information, visit www.creativemedicaltechnology.com
Forward-Looking Statements
This press release contains forward-looking statements regarding clinical development, regulatory strategy and positioning, commercialization potential, and market opportunity. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Factors include clinical trial outcomes, regulatory decisions, manufacturing considerations, competitive dynamics, and market conditions. Please refer to the Company’s filings with the SEC for a discussion of these risks. The Company undertakes no obligation to update forward-looking statements except as required by law.
Investor & Media Contacts
Creative Medical Technology Holdings, Inc.
IR@CreativeMedicalTechnology.com
www.creativemedicaltechnology.com
Investor Relations
Devin Sullivan — The Equity Group Inc.
dsullivan@theequitygroup.com
Conor Rodriguez — The Equity Group Inc.
crodriguez@theequitygroup.com
RedChip Companies
Dave Gentry — CELZ@redchip.com | 1-407-644-4256
Paul Kuntz — paul@redchip.com | 412-708-4590
FAQ**
How does Creative Medical Technology Holdings Inc. CELZ plan to utilize the proposed INN "etaroleucel" for its CELZ-101 immunotherapy program in addressing Type 1 diabetes?
What are the anticipated clinical applications and market potential for Creative Medical Technology Holdings Inc. CELZ's CELZ-201 (olastrocel) in treating chronic lower back pain?
Can Creative Medical Technology Holdings Inc. CELZ outline the regulatory pathways it is following to ensure successful commercialization of both CELZ-101 and CELZ-201?
What strategies does Creative Medical Technology Holdings Inc. CELZ have in place to manage the risks and uncertainties associated with their clinical development and regulatory execution?
**MWN-AI FAQ is based on asking OpenAI questions about Creative Medical Technology Holdings Inc. (NASDAQ: CELZ).
NASDAQ: CELZ
CELZ Trading
-1.07% G/L:
$1.85 Last:
3,252 Volume:
$1.81 Open:
